Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $81.4545.

VERA has been the subject of a number of research analyst reports. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a research report on Wednesday, March 11th. HC Wainwright boosted their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st.

Vera Therapeutics Stock Down 1.6%

VERA opened at $41.61 on Thursday. Vera Therapeutics has a 1-year low of $18.76 and a 1-year high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -8.93 and a beta of 1.17. The business has a 50 day moving average of $41.16 and a 200-day moving average of $39.84.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter in the prior year, the company earned ($0.72) earnings per share. As a group, sell-side analysts anticipate that Vera Therapeutics will post -5.33 earnings per share for the current year.

Insider Buying and Selling at Vera Therapeutics

In related news, insider William D. Turner sold 2,187 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares in the company, valued at $1,902,239.74. This trade represents a 4.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laurence Matthew Skelton sold 1,582 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $66,412.36. Following the transaction, the insider owned 64,218 shares of the company’s stock, valued at $2,695,871.64. This trade represents a 2.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 56,441 shares of company stock worth $2,416,902 in the last 90 days. 16.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $46,000. Quantbot Technologies LP bought a new stake in Vera Therapeutics during the 2nd quarter worth approximately $51,000. Aster Capital Management DIFC Ltd bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $71,000. Finally, Tower Research Capital LLC TRC grew its position in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.